Rehovot, Israel, December 2025 — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, has announced the appointment of Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026.
Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience bridging science, business and funding. She has led R&D, clinical development and business operations across the pharmaceutical, diagnostics and agri-biotechnology sectors. Her professional journey includes leadership roles as Chief Executive Officer and Co-Founder of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX, and QC Domain Manager at Teva Pharmaceutical Industries.
Dr. Nissan holds a PhD and completed postdoctoral research in biochemistry and proteomics at the Weizmann Institute of Science.
“I am excited to join Evogene at a pivotal time in its expansion,” said Dr. Olga Nissan. “The company’s commitment to translating cutting-edge, AI-driven science into meaningful small-molecule-based therapeutic value, strongly aligns with my experience across pharma and biotech. I look forward to building strategic partnerships, advancing innovative discovery programs, and working with Evogene’s talented team to accelerate the delivery of impactful solutions for patients and partners worldwide.”
Mr. Ofer Haviv, President and Chief Executive Officer of Evogene, added: “We are delighted to welcome Dr. Olga Nissan to Evogene’s leadership team. With more than 15 years of experience spanning biotech, pharma, and AI-enabled drug discovery, Olga brings a unique combination of scientific depth, business development leadership, and company-building expertise. We believe her capabilities will be instrumental as we scale our small-molecule discovery and optimization offering, powered by our ChemPass AI tech-engine, and expand collaborations with leading industry partners – translating real-world innovation into meaningful value.”
About Evogene
Evogene Ltd. is a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. Its proprietary ChemPass AI generative engine enables the design of novel, highly potent small molecules optimized across multiple critical parameters, significantly improving development success rates while reducing time and cost. Through strategic partnerships and internal product development, Evogene continues to advance breakthrough products driven by real-world innovation.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
